In this episode, guest John E. Harris, MD, PhD, discusses how vitiligo occurs and how dermatologists can navigate the vitiligo treatment landscape. •    Intro 0:28 •    John E. Harris, MD, PhD 0:41 •    How does vitiligo occur, and what is the basic science behind it?  1:08 •    Are there any known triggers of this condition in people who have genetic susceptibility to it?  3:19 •    How does drug-induced vitiligo occur in people?  4:42 •    When you see a patient with vitiligo, how do you approach the patient to establish a diagnosis?  6:03 •    Given that this is an autoimmune disease, do you routinely screen vitiligo patients for things like their thyroid function and B12 levels? 9:54 •    What about the pernicious anemia aspect of things? 10:36 •    Tell us a little bit about the treatment landscape, and how you counsel patients. 12:26 •    Who is a good candidate for these new treatment options, and what success rate do you quote over a period of time? 14:06 •    When do you bring patients back in for follow-ups? 14:59 •    How often are you administering combination therapy? 15:30 •    Does narrow band UVB work synergistically with other therapies, or is it more of an added measure? 16:20 •    How do you manage patients who have early extensive active vitiligo? 17:08 •    If someone has facial vitiligo in a non-pigmented area, do you still treat that patient? 18:01 •    Thank you, Dr. Harris. 19:09 John E. Harris, MD, PhD, is professor and chair of the Department of Dermatology and founding director of the Vitiligo Clinical Research Center, as well as the founding director of the Autoimmune Therapeutics Institute at UMass Chan Medical School.

We’d love to hear from you! Send your comments/questions to Dr. Gelfand at [email protected]. Follow Dr. Gelfand on LinkedIn.

For more, be sure to visit the Beneath the Surface video blog on Healio.com. 

Disclosures: Gelfand reports no relevant financial disclosures. Harris reports having financial relationships with AbbVie, Aclaris Therapeutics, Admirx, Aldena Therapeutics, Almirall, AnaptysBio, Avita, BiologicsMD, Boston Pharma, Celgene, Cogen Therapeutics, Dermavant, Dermira, EMD Serono, Expert Institute, Frazier Management, Genzyme/Sanofi, Incyte, Janssen, LEO Pharma, Methuselah Health, NIRA Biosciences, Pandion, Pfizer, Rheos Medicines, Sonoma Biotherapeutics, Stiefel/GSK, Sun Pharmaceuticals, Temprian Therapeutics, TeVido BioDevices, 3rd Rock Ventures, TWi Biotech, Villaris Therapeutics and Vimela Therapeutics.